Welcome to our dedicated page for Passage Bio news (Ticker: PASG), a resource for investors and traders seeking the latest updates and insights on Passage Bio stock.
Passage Bio, Inc. (NASDAQ: PASG) delivers cutting-edge gene therapies targeting rare central nervous system disorders through innovative AAV vector technology. This news hub provides investors and researchers with timely updates on clinical advancements, strategic partnerships, and operational developments shaping the company's trajectory in genetic medicine.
Access authoritative reporting on PASG's lead programs including PBGM01 for GM1 gangliosidosis and PBFT02 for frontotemporal dementia. Our curated news collection features regulatory milestones, trial data disclosures, and analysis of licensing agreements with academic and industry partners.
Key updates cover three critical areas: clinical trial progress across neurodegenerative targets, research collaborations enhancing therapeutic platforms, and strategic operational decisions supporting sustainable development. Bookmark this page for consolidated access to PASG's evolving position in gene therapy innovation.
Passage Bio (Nasdaq: PASG) has appointed Eliseo O. Salinas, M.D., MSc, as its new chief research & development officer. Previously with Acadia Pharmaceuticals, Salinas brings over 30 years of experience in R&D leadership and expertise in neuroscience and rare diseases. His appointment aims to strengthen Passage Bio's pipeline and support its transition to a clinical-stage company with multiple assets. Salinas is expected to enhance the R&D team's capabilities to advance innovative gene therapies targeting rare CNS disorders, in collaboration with the University of Pennsylvania's Gene Therapy Program.
Passage Bio has received FDA Fast Track designation for its lead gene therapy candidates: PBGM01 for GM1 gangliosidosis, PBFT02 for frontotemporal dementia with granulin mutations, and PBKR03 for Krabbe disease. This designation will expedite their development and review processes. Clinical trials for PBGM01 will initiate in Q1 2021, followed by PBFT02 and PBKR03 in H1 2021. The company aims to meet urgent treatment needs for rare neurological diseases and has also secured various designations from regulatory agencies.
Passage Bio (NASDAQ: PASG) is advancing its clinical programs for rare CNS disorders, with three Phase 1/2 trials set to begin in H1 2021. The company has initiated patient recruitment for its PBGM01 trial for GM1 gangliosidosis and has cleared regulatory hurdles for PBKR03 (Krabbe disease) and PBFT02 (frontotemporal dementia). Following a public offering, the company strengthened its finances, raising $166M. As of December 31, 2020, cash reserves stood at $304.8M. Despite a net loss of $112.2M for 2020, Passage Bio is poised for development milestones and expanding its pipeline.
Passage Bio (NASDAQ: PASG) announced participation in two virtual investor conferences in March 2021. The first is the Barclay’s Global Healthcare Conference on March 10, at 4:10 p.m. ET, featuring a presentation format. The second event is the Stifel 3rd Annual CNS Day on March 31, at 10:00 a.m. ET, in a fireside chat format. Both events will be webcast live, with replays available for 30 days. Passage Bio focuses on gene therapies for rare central nervous system disorders, collaborating with the University of Pennsylvania's Gene Therapy Program.
Passage Bio (NASDAQ: PASG) announced a conference call on March 3, 2021, at 8:30 a.m. ET to discuss its fourth quarter and full-year 2020 financial results. This call will provide key insights into the company's recent business highlights. Investors can join via phone or through a live audio webcast. The call will be archived for 30 days. Based in Philadelphia, Passage Bio is focused on developing gene therapies for rare central nervous system disorders, collaborating with the University of Pennsylvania to further its preclinical work and enhance its pipeline.
Passage Bio (Nasdaq: PASG) has appointed Dr. Maxine Gowen to its board of directors, effective February 18, 2021. Dr. Gowen, CEO of Tamuro Bio, brings extensive leadership experience from her tenure at Trevena and GSK. Her expertise is expected to support Passage Bio's transition into a clinical development organization. Simultaneously, Dr. Stephen Squinto has resigned from his board position after significant contributions, including advancing the company’s pipeline and supporting its IPO. Passage Bio aims to develop transformative gene therapies for rare CNS disorders.
Passage Bio (Nasdaq: PASG) announced FDA clearance for its IND application for PBKR03, a gene therapy targeting early infantile Krabbe disease, with clinical trials expected to start in 1H21. Krabbe disease, a rare CNS disorder, lacks approved therapies, highlighting the urgency of this development. PBKR03 utilizes a proprietary AAV capsid for gene delivery, aiming to restore GALC activity in affected patients. Preclinical studies show promising results, indicating potential for improved myelination and survival rates.
Passage Bio, Inc. (Nasdaq: PASG) announced FDA clearance for the IND application of PBFT02, a gene therapy for Frontotemporal Dementia (FTD) with GRN mutations, a condition with no approved disease-modifying treatments. Preclinical data from the University of Pennsylvania demonstrated PBFT02’s potential to elevate PGRN levels in the brain and cerebrospinal fluid while reducing lysosomal storage lesions. A Phase 1/2 clinical trial is expected to commence in H1 2021, focusing on safety, tolerability, and biomarker assessment, with initial data anticipated by late 2021 or early 2022.
Passage Bio, Inc. (Nasdaq: PASG) has priced its public offering of 7 million shares of common stock at $22.00 per share, aiming to raise $154 million in gross proceeds. The offering, which includes a 30-day option for underwriters to purchase an additional 1.05 million shares, is expected to close around January 26, 2021. The proceeds will support the company's efforts in gene therapies for rare central nervous system disorders. J.P. Morgan, Goldman Sachs, and Cowen are the joint bookrunning managers for the offering.
Passage Bio (Nasdaq: PASG) has announced a public offering of 7,000,000 shares of its common stock, with an additional 1,050,000 shares available through underwriters' options. This offering is intended to raise capital for the company's operations focusing on gene therapies for rare neurological disorders. J.P. Morgan, Goldman Sachs, and Cowen are managing the offering. The registration is pending approval from the SEC, and the offering's completion is uncertain.